We report a 42 years old HIV negative male admitted for fever of unknown origin. Initial laboratory evaluation showed elevated hepatic transaminases and alkaline phosphatase and an hipodense hepatic imagen was visualized in the CT scan. Hepatic biopsy demonstrated tuberculous granulomas and alcohol fast acid rods with Ziehl Neelsen stain. Anti-tuberculous treatment resulted in resolution of fever, improvement of general condition and normalization of laboratory parameters.
Introduction: In the beginning of pandemic, we emphasized on "the benefit to few versus risk to many" as a caution for continuing elective transplantation in resource limited nations like India. Methods: Here we summarize all our research experience during the pandemic.Results: We reported the comparative impact of pandemic from India in single center, national wide, and global observatory data on organ donation and transplantation. There was 50% decline in deceased donation transplantation in India contrasting with America, which was able to cope with the initial decline in transplants via a well-equipped deceased donation system. We contributed to National Organ and Tissue Transplant Organization (NOTTO), Transplant Specific Guidelines for COVID-19, NOTTO COVID-19 Vaccine Guidelines, NOTTO guidelines for Vaccine-induced thrombotic thrombocytopenia in organ donation, and consensus statement for kidney transplant recipient (KTR) and donor with a previous diagnosis of COVID-19. We first time reported that mortality rates in Southeast Asian KTR (n=250) with COVID-19 infection appear to be higher than those in nonimmunosuppressed patients in our multicenter project. In nationwide data, we reported mortality in early kidney transplant recipients to be lower, and waitlisted patients to be higher which suggests, immunosuppression as per se is not an important factor in halting transplantation. We reported a different clinical spectrum of COVID-19 amongst KTR with similar mortality between the two waves. We were the first one to report safety of remdesivir (n=57) and convalescent plasma therapy (n=10) in organ transplant recipients. We reported the largest retrospective, multicentre, cohort study of KTR (n=31) from living donors who recovered from COVID-19, KTR (n=372) after recovery from COVID-19, COVID-19-associated mucormycosis (CAM) with 4.4% incidence of CAM and 26.2% mortality, and with reoccurring SARS-CoV-2 infection(n=13), with 46% mortality. Our reports suggest that transplantation from COVID-19 donors may be feasible and safe, at least in short-term follow-up. In general, continuing a standard immunosuppression regimen may be reasonable, except in cases of inadvertent transplantation with active SARS-CoV-2. We reported COVID-19 vaccine safety with suboptimal efficacy in KTR and dialysis patients in a single-center experience. More research is needed to guide the optimal approach to a vaccination before and after transplantation. Conclusion:We are continuing our research on vaccine efficacy, booster doses, and follow-up sequelae. Further policy-making and preparedness are required to safeguard the most vulnerable areas of the world to minimize the impact of any future pandemic on transplantation practices.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.